Chardan Capital analyst Gbola Amusa maintained a Hold rating on Voyager Therapeutics Inc (VYGR) today and set a price target of $30. The company’s shares opened today at $23.53.
Amusa commented:
“We maintain a Neutral rating due to our view: (1) Voyager has relatively few important 2019 catalysts, and (2) key valuation inflection points are more than 1 year away. Sanofi Genzyme is giving up rights to Voyager’s AAV-based GT programs in Huntington’s disease (HD) and Friedreich’s ataxia (FA) in exchange for $10-$20 mm in payments, plus low-single-digit royalties in HD. We understand that under the restructuring, Voyager is no longer entitled to receive “up to $540.0 million” milestones from Sanofi Genzyme, per the recent 10-Q. Under the new terms, Sanofi will return the worldwide rights to VY-HTT01 in HD and the ex-US rights to VY-FXN01 in FA; and, Voyager will make an upfront payment of $10 mm to Sanofi.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.6% and a 51.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Logicbio Therapeutics Inc, Axovant Gene Therapies, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Voyager Therapeutics Inc with a $26.50 average price target.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.17 million. In comparison, last year the company had a GAAP net loss of $19.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
